Advertisement

Topics

Array Submits NDA to FDA for Binimetinib and Encorafenib in Advanced Melanoma

09:44 EDT 5 Jul 2017 | Speciality Pharma Journal

BOULDER, Colo., July 5, 2017 /PRNewswire/ — Array BioPharma (Nasdaq:  ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant …

Original Article: Array Submits NDA to FDA for Binimetinib and Encorafenib in Advanced Melanoma

NEXT ARTICLE

More From BioPortfolio on "Array Submits NDA to FDA for Binimetinib and Encorafenib in Advanced Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...